| Human Genome Sciences |
Article Index for Human Genome |
Website Links For Human |
Information AboutHuman Genome Sciences |
| CATEGORIES ABOUT HUMAN GENOME SCIENCES | |
| companies in the nasdaq biotechnology index | |
| companies based in maryland | |
| companies established in 1992 | |
| biotechnology companies | |
|
Its opulent facilities in Rockville, Maryland earned its architect—Davis Carter Scott, Ltd.—an award from the National Association of Industrial and Office Properties. The Association cited the Glass Wall s, Atrium , and uniform Design of all the Building s as reasons for the award. The company was founded by William Haseltine, a former Harvard University AIDS researcher with a notorious ego. HGS had a partnership for several years after its founding with Craig Venter and his non-profit TIGR to begin sequencing and submitting patents on hundreds of thousands of protein-encoding DNA fragments. In 2000, Haseltine said that his work "speeds up biological discovery a hundredfold, easily. Easily." He talked of finding in genes "the fountain of youth" in the form of "cellular replacement" therapies. More than $1 billion was invested in the company in 2000. But initial drugs failed in initial clinical trials, and the stock plummeted. HGS currently has therapies under development for lupus as well as albumin fusion proteins for existing biotherapeutic proteins. For example, in September 2000, the company reported that it had found a way to treat large, painful sores that often plague elderly patients, using a protein spray called repifermin, made by a human gene called keratinocyte growth factor-2. Reporting on a Phase IIa clinical trial, Haseltine said "Those who got the drug grew almost 10 times as much skin as people who did not get any." In September 2003, the company reported that it would end the development of the drug for use in venous ulcers (sores) because of disappointing clinical trial results, but would continue a mid-stage (Phase II) trial of repifermin in the treatment of mucositis, an inflammation of the mouth that some chemotherapy patients develop. In February 2004, the company said that it was ending the development of repifermin because it showed no more benefit than a placebo in clinical trials. BIBILOGRAPHY
EXTERNAL LINK |
|
|